补体总活性（CH50）作为视神经脊髓炎谱系障碍中依库珠单抗治疗的一种潜在生物标志物。
CH50 as a putative biomarker of eculizumab treatment in neuromyelitis optica spectrum disorder.
作者信息
Namatame Chihiro, Misu Tatsuro, Takai Yoshiki, Nishiyama Shuhei, Nakashima Ichiro, Fujihara Kazuo, Aoki Masashi
机构信息
Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
Department of Neurology, Tohoku Medical and Pharmaceutical University, Sendai, Miyagi, Japan.
出版信息
Heliyon. 2021 Jan 8;7(1):e05899. doi: 10.1016/j.heliyon.2021.e05899. eCollection 2021 Jan.
Here we report 3 cases of neuromyelitis optica spectrum disorder (NMOSD), who were all treated with eculizumab and could be observed with monitoring serum C3, C4 and 50% hemolytic complement (CH50) before and after the treatment. Serum C3 and C4 were not dramatically changed during the treatment, in contrast serum CH50 level of each patient had diminished and kept under the detection limit after the treatment without clinical worsening, even in the situation of extending dosing. Serum CH50 level is useful to monitor the drug efficacy during eculizumab treatment.
在此，我们报告3例视神经脊髓炎谱系障碍（NMOSD）患者，他们均接受了依库珠单抗治疗，并且在治疗前后可监测血清C3、C4和50%溶血补体（CH50）。治疗期间血清C3和C4没有显著变化，相反，每位患者的血清CH50水平均有所下降，且在治疗后一直保持在检测限以下，即使在延长给药的情况下也没有临床病情恶化。血清CH50水平有助于监测依库珠单抗治疗期间的药物疗效。
Zotero 插件